Company: SMNR
Filing Date: 2025-07-28
Form Type: 425
Source: 0001213900-25-068268
Chunk: 4

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-28
Form: 425
Chunk 4
---

risk that the Business Combination disrupts current plans and operations as a result of the announcement and consummation of the Business
Combination; the ability of the combined company to grow and manage growth profitably and retain its key employees; the amount of redemption
requests made by Denali’s shareholders; the inability to obtain or maintain the listing of the post-acquisition company’s
securities on Nasdaq or OTC Markets following the Business Combination; and costs related to the Business Combination. There may be additional
risks that Denali presently does not know or that Denali currently believes are immaterial that could also cause actual results to differ
from those contained in the forward-looking statements. In addition, forward-looking statements provide Denali’s expectations, plans
or forecasts of future events and views as of the date of this communication. Denali anticipates that subsequent events and developments
will cause such assessments to change. However, while Denali may elect to update these forward-looking statements at some point in the
future, Denali specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing
Denali’s assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed
upon the forward-looking statements.

Disclaimer

This communication is for
informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities
or the solicitation of any vote in any jurisdiction pursuant to the Business Combination or otherwise, nor shall there be any sale, issuance
or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means
of a prospectus meeting the requirements of Section 10 of the Securities Act.

Item 9.01. Financial Statement and Exhibits.

(d) Exhibits.

| Exhibit No. 
 2.1         |     | Description                                                                                                                                                                                                                                                                                               
 Amendment No. 2 to Agreement and Plan of Merger, dated as of July 22, 2025, by and among Denali Capital Acquisition Corp., Denali Merger Sub Inc. and Semnur Pharmaceuticals, Inc. (incorporated by reference to Exhibit 2.1 to Scilex’s Current Report on Form 8-K filed with the SEC on July 23, 2025). |
|:------------|:----|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 104         |     | Cover Page Interactive Data File